Skip to main content

DeCode Awarded $24 Million by NIH to Study Genetics of Infectious Disease and Vaccine Response

NEW YORK, Oct. 8 (GenomeWeb News) - DeCode genetics announced today that it has been awarded a five-year, $23.9 million contract by the National Institute of Allergy and Infectious diseases to discover genetic factors associated with susceptibility to certain infectious diseases. The Raykjavik, Iceland-based company will also apply its population-based research approach to investigate genetic factors associated with vaccine response.

 

More specifically, the contract states that DeCode will conduct genome-wide scans in Icelandto search for key genes involved in susceptibility to tuberculosis; adverse reaction to smallpox vaccination; and susceptibility to influenza and certain bacterial infections, such as those that cause pneumonia and meningitis.

 

Following the identification of targets by DeCode, a team at the Universityof New Mexicoled by Rick Lyons will conduct functional validation studies on the targets. In addition, the NationalCenterfor Genome Resources, headed by Stephen Kingsmore, will design and maintain an internet-based Immune Response database that will enable investigators to query and visualize results of the project in the context of existing data on the genetics of immune response.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.